UFP Technologies, Inc. (UFPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$288.79+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
UFP focuses on fast-growing medical tech like robotic surgery. Sales grew 4.1% last year. The company plans new factories in the Dominican Republic. Profit per share is expected above $2.24 next year.
Growth could slow if medical tech demand weakens. New factories might not boost sales fast. Profit per share could fall below $2.24 next year.
The price is about 8% above our fair value near $251. Analysts expect 7.6% revenue growth. We agree with these views.
Breaks if: Facilities not operational by end of 2026
Breaks if: EPS guidance falls below $2.24 for FY26
Breaks if: YoY revenue growth falls below 7.6% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
UFPT represents a durable compounder in the healthcare sector. The company is focusing on growth through expanding facilities and targeting high-growth MedTech segments, which supports its long-term outlook.
The current valuation is elevated, reflecting market expectations that may not be justified given the company's execution quality. The market seems to have priced in a premium compared to peers, indicating a potential expectations gap.
Recent financial performance has been strong, with revenue growth driven by medical sales. Management is on track with its priorities, although there is some near-term margin pressure from capacity expansion efforts.
The thesis hinges on the company's ability to maintain guidance and navigate potential economic headwinds, such as a weakening jobs report. Additionally, performance from sector bellwethers could influence UFPT's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis. However, record profits come with complicated margins, which threaten revenue growth. Additionally, recent stock sales by leadership raise concerns about stability.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, UFPT's fundamentals are solid, but the elevated valuation and potential risks warrant careful monitoring. Not investment advice.